TP53 and neoplasm: For instance, the detection of a TP53 variant in the blood from a patient with metastatic high grade serous ovary carcinoma is likely to correspond to circulating tumour DNA, considering the very high frequency of somatic TP53 alterations in these malignancies (>95%); the second is due to clonal haematopoiesis, corresponding to the occurrence, in hematopoietic stem cells of somatic TP53 alterations conferring a growth advantage.